CH418528A - Verfahren zur Herstellung einer neuen als Arzneimittel zur oralen Verabreichung geeigneten amprotropinhaltigen Zubereitung - Google Patents

Verfahren zur Herstellung einer neuen als Arzneimittel zur oralen Verabreichung geeigneten amprotropinhaltigen Zubereitung

Info

Publication number
CH418528A
CH418528A CH709962A CH709962A CH418528A CH 418528 A CH418528 A CH 418528A CH 709962 A CH709962 A CH 709962A CH 709962 A CH709962 A CH 709962A CH 418528 A CH418528 A CH 418528A
Authority
CH
Switzerland
Prior art keywords
amprotropin
medicament
new
production
oral administration
Prior art date
Application number
CH709962A
Other languages
English (en)
Inventor
Koff Arnold
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CH418528A publication Critical patent/CH418528A/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/795—Polymers containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CH709962A 1961-06-16 1962-06-13 Verfahren zur Herstellung einer neuen als Arzneimittel zur oralen Verabreichung geeigneten amprotropinhaltigen Zubereitung CH418528A (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US117505A US3138525A (en) 1961-06-16 1961-06-16 Castor wax-amprotropine-resin compositions

Publications (1)

Publication Number Publication Date
CH418528A true CH418528A (de) 1966-08-15

Family

ID=22373300

Family Applications (1)

Application Number Title Priority Date Filing Date
CH709962A CH418528A (de) 1961-06-16 1962-06-13 Verfahren zur Herstellung einer neuen als Arzneimittel zur oralen Verabreichung geeigneten amprotropinhaltigen Zubereitung

Country Status (3)

Country Link
US (1) US3138525A (de)
CH (1) CH418528A (de)
GB (1) GB935639A (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1792233B1 (de) * 1967-08-12 1971-10-07 Geigy Ag J R Verfahren zur Stabilisierung eines oralen,fluessigen Arzneimittels auf der Basis von Imipramin und einem Ionenaustauscherharz

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3499960A (en) * 1965-01-25 1970-03-10 Merck & Co Inc Palatable coated particles of an anion exchange resin
US4221778A (en) * 1979-01-08 1980-09-09 Pennwalt Corporation Prolonged release pharmaceutical preparations
US4762709A (en) * 1983-09-16 1988-08-09 Pennwalt Corporation Liquid prolonged release pharmaceutical formulations containing ionic constituents
AU565487B2 (en) * 1983-09-16 1987-09-17 Fisons Corporation Liquid prolonged release pharmaceutical formulations containing ionic constituents
FR2576213B1 (fr) * 1985-01-21 1989-02-24 Cortial Nouveau procede d'obtention de formes pharmaceutiques a liberation prolongee
ES8604955A1 (es) * 1985-11-08 1986-03-16 Covex Sa Procedimiento para la preparacion de resinatos de la (-) eburnamenina-14-(15h)-ona
US4894239A (en) * 1987-06-02 1990-01-16 Takeda Chemical Industries, Ltd. Sustained-release preparation and production thereof
IL90245A (en) * 1988-05-11 1994-04-12 Glaxo Group Ltd Resin adsorption containing ranitidine together with synthetic resin replaces cations, its preparation and pharmaceutical preparations containing it
US5219563A (en) * 1988-05-11 1993-06-15 Glaxo Group Limited Drug adsorbates
US4996047A (en) * 1988-11-02 1991-02-26 Richardson-Vicks, Inc. Sustained release drug-resin complexes
CA2002492A1 (en) * 1988-11-11 1990-05-11 Sandra T. A. Malkowska Pharmaceutical ion exchange resin composition
US5186930A (en) * 1988-11-14 1993-02-16 Schering Corporation Sustained release oral suspensions
US5320848A (en) * 1991-05-28 1994-06-14 Affinity Biotech, Inc. Chewable drug-delivery composition
CA2309597A1 (en) 1997-11-10 1999-05-20 Hiroshi Sorimachi Sustainedly releasing agents for medicines and sustainedly released medicinal compositions containing the same
ATE251449T1 (de) 1999-06-14 2003-10-15 Cosmo Spa Geschmacksmaskierte orale pharmazeutische zusammensetzungen mit kontrollierter abgabe
US8895064B2 (en) 1999-06-14 2014-11-25 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
KR100736024B1 (ko) * 2005-09-21 2007-07-06 주식회사종근당 신규한 클로피도그렐 우선성 광학이성체의 이온교환수지착체와 그 제조방법
RU2435569C2 (ru) 2006-03-16 2011-12-10 Трис Фарма, Инк. Композиции с модифицированным высвобождением, содержащие комплексы лекарственное вещество - ионообменная смола
WO2008042218A1 (en) 2006-10-03 2008-04-10 Tris Pharma, Inc. Formulations containing an ionic mineral-ion exchange resin complex and uses thereof
US20130230587A1 (en) 2010-11-10 2013-09-05 Rubicon Research Private Limited Sustained release compositions
RS54447B1 (en) 2011-01-20 2016-06-30 Bionevia Pharmaceuticals Inc. MODIFIED LABELING COMPOSITIONS OF EPALRESTAT OR ITS DERIVATIVES AND PROCEDURES FOR THEIR USE
US10154964B2 (en) 2011-09-07 2018-12-18 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
BR112015003120B1 (pt) 2012-08-15 2022-08-09 Tris Pharma , Inc Tablete mastigável de liberação estendida de metilfenidato e seu uso
US20170128379A1 (en) * 2014-06-30 2017-05-11 Rubicon Research Private Limited Modified release pharmaceutical preparations
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
WO2019126215A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Ghb pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
EP3740189A1 (de) 2017-12-18 2020-11-25 Tris Pharma, Inc. Arzneimittelpulverzusammensetzung mit modifizierter freisetzung mit gastro-retentiven raft-bildenden systemen mit triggerimpuls-arzneimittelfreisetzung
US11337920B2 (en) 2017-12-18 2022-05-24 Tris Pharma, Inc. Pharmaceutical composition comprising GHB gastro-retentive raft forming systems having trigger pulse drug release

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2805977A (en) * 1955-01-04 1957-09-10 Smith Kline French Lab Sustained release pharmaceutical preparation
US2990332A (en) * 1958-04-02 1961-06-27 Wallace & Tiernan Inc Pharmaceutical preparations comprising cation exchange resin adsorption compounds and treatment therewith

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1792233B1 (de) * 1967-08-12 1971-10-07 Geigy Ag J R Verfahren zur Stabilisierung eines oralen,fluessigen Arzneimittels auf der Basis von Imipramin und einem Ionenaustauscherharz

Also Published As

Publication number Publication date
US3138525A (en) 1964-06-23
GB935639A (en) 1963-09-04

Similar Documents

Publication Publication Date Title
CH418528A (de) Verfahren zur Herstellung einer neuen als Arzneimittel zur oralen Verabreichung geeigneten amprotropinhaltigen Zubereitung
AT238716B (de) Verfahren zur Herstellung von neuen Derivaten des 7-Oxycumarins
AT244317B (de) Verfahren zur Herstellung von neuen Farnesylesigsäureestern
AT239788B (de) Verfahren zur Herstellung von neuen β-Carbolin-carbonsäureamid-Derivaten
AT238720B (de) Verfahren zur Herstellung von neuen 6,11-Dihydro-dibenz(b,e)-thiepin-Derivaten
CH469093A (de) Verfahren zur Herstellung eines neuen Impfstoffes gegen Panleucopenia
CH418340A (de) Verfahren zur Herstellung eines neuen Derivats des 1,3-Diazacyclopentens
AT240865B (de) Verfahren zur Herstellung von neuen Thiaxanthen-Derivaten
AT265513B (de) Verfahren zur Herstellung von neuen Cephalosporinderivaten
AT249885B (de) Verfahren zur Herstellung eines neuen Hexapeptids
CH379507A (de) Verfahren zur Herstellung von neuen 10-(1'-Hydroxyalkyl-pyrrolidyl-(3')-methyl)-phenothiazinen
CH385854A (de) Verfahren zur Herstellung von neuen Iminodibenzylderivaten
AT243272B (de) Verfahren zur Herstellung von neuen Oxazinderivaten
CH407120A (de) Verfahren zur Herstellung von neuen Piperidinderivaten
CH426847A (de) Verfahren zur Herstellung von neuen therapeutisch wirksamen Pyrazolonderivaten
CH386428A (de) Verfahren zur Herstellung von neuen Iminodibenzylderivaten
AT246139B (de) Verfahren zur Herstellung von neuen Piperidinderivaten
AT240849B (de) Verfahren zur Herstellung von neuen 5-Nitrofuran-Derivaten
AT262502B (de) Verfahren zur Herstellung einer stabilen und pharmazeutisch verwendbaren Insulinlösung
AT250572B (de) Verfahren zur Herstellung von neuen Heptapeptidderivaten
AT241472B (de) Verfahren zur Herstellung von neuen 1-Azathiaxanthenderivaten
CH419147A (de) Verfahren zur Herstellung einer neuen heterocyclischen Verbindung
AT242147B (de) Verfahren zur Herstellung von neuen 4-Hydroxy-5-halogen-pyrimidinderivaten
AT255661B (de) Verfahren zur Herstellung von neuen 1-Cyancolchicinderivaten
AT252451B (de) Verfahren zur Herstellung einer oralen Arzneizubereitung